Artia Global Partners LP purchased a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) in the fourth quarter, Holdings Channel reports. The firm purchased 41,570 shares of the company’s stock, valued at approximately $755,000.
Other large investors have also made changes to their positions in the company. UBS Group AG grew its position in shares of Avalo Therapeutics by 956.9% in the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after purchasing an additional 432,608 shares in the last quarter. Patient Square Capital LP purchased a new position in Avalo Therapeutics in the third quarter worth approximately $1,271,000. Moody Aldrich Partners LLC purchased a new position in Avalo Therapeutics in the fourth quarter worth approximately $2,419,000. Cantor Fitzgerald L. P. purchased a new position in Avalo Therapeutics in the third quarter worth approximately $1,083,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in Avalo Therapeutics in the fourth quarter worth approximately $3,432,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
AVTX has been the subject of several analyst reports. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Citizens Jmp lowered their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Bank of America initiated coverage on Avalo Therapeutics in a research report on Friday, June 12th. They issued a “buy” rating and a $35.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.67.
Avalo Therapeutics Stock Up 7.5%
AVTX opened at $15.40 on Thursday. Avalo Therapeutics, Inc. has a 52 week low of $4.47 and a 52 week high of $24.27. The business has a fifty day simple moving average of $15.53 and a 200-day simple moving average of $16.12. The firm has a market cap of $809.58 million, a P/E ratio of -2.82 and a beta of 0.83.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. Sell-side analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.
Insider Activity
In other news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares in the company, valued at approximately $5,596.29. This trade represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the completion of the sale, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 112,586 shares of company stock worth $2,089,651. Corporate insiders own 4.46% of the company’s stock.
Avalo Therapeutics Profile
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report).
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
